Table 23. Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches.
| Author/ Years/ Country | 1-yr SR (%) | 2-yr SR (%) | 3-yr SR (%) | 4-yr SR (%) | 5-yr SR (%) | Mortality Rate (%) |
Morbidity Rate (%) |
Median OS (mo) |
OS 95% CI (mo) |
PFS(95% CI) (mo) | DFS/RFS (95% CI) (mo) |
Follow-up times (range) (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIPEC single arm studies | ||||||||||||
| Hompes/ 2014/ Belgium [59] | ≈91 (L-OHP) ≈88 (MMC) |
≈68 (L-OHP) ≈59 (MMC) |
≈53 (L-OHP) ≈42 (MMC) |
≈45 (L-OHP) ≈33 (MMC) |
NA | 0 | 41.1 | 37.1 (L-OHP) 26.5 (MMC) |
22.4-52.8 (L-OHP) 16.9-64.8 (MMC) |
NR | 12.2 (7.2-undefined) (L-OHP) 13.8(7.0-25.8) (MMC) (RFS) |
33.6 (L-OHP) 61.2 (MMC) |
| Iversen/ 2013/ Denmark [60] | ≈97 | 60 | 47 | 38 | 38 | 2.9 | 32.4 | ≈31 | NR | NR | NR | 16.0 (0.9–71.3) |
| Kecmanovic/ 2005/ Serbia and Montenegro [61] | ≈85 | ≈85 | ≈85 | ≈85 | NA | 0 | 44.4 | 15 | 1-57 | NR | NR | 21 (1-56) |
| Kianmanesh/ 2007/ France [62] | ≈95 | 72 | ≈57 | 44 | 44 | 2.3 | 39 | 38.4 | 32.8-43.9 | NR | NR | NR |
| Klaver/ 2011/ Netherlands [63] | 71 | ≈56 | ≈43 | ≈35 | ≈18 | NR | NR | 28 | 3-100 | NR | NR | NR |
| Klaver/ 2012/ Netherlands [64] | 83 | ≈52 | ≈26 | ≈26 | NA | 0 | 33.3 | 35 | 20.0-49.9 | NR | 12 (7.7-16.3) | 10.5 (1-52) |
| Kuijpers/ 2013/ Netherlands [65] | ≈84 | ≈62 | 46 | ≈37 | 31 | 3 included PMP |
34 included PMP |
33 | 28-38 | 15 (13–17) | NR | 41 (35-46) included PMP |
| Kuijpers/ 2014/ Netherlands [66] | ≈87 | ≈62 | 45 | ≈37 | ≈32 | 0 | 30 | 30 | 19-41 | 15 (14-16) | NR | 47 (43-51) |
| Lanuke/ 2009/ Canada [67] | ≈85 | ≈58 | ≈46 | NA | NA | 4 (all) | 39 (all) | 26 | 1-48 | NR | 8 (1-31) | 12 (1-48) |
| Levine/ 2014/ America [68] | ≈69 | ≈38 | ≈27 | ≈19 | ≈17 | 3.8 (all) | 42 (all) | ≈19 | NR | NR | NR | NR |
| Maillet/ 2016/ France [101] | NR | NR | 58 | NR | 34 | 4 | NR | 43.3 | NR | 12.4 | NR | NR |
| McConnell/ 2013/ Canada [69] | NR | NR | NR | NR | NR | 0 | 36.9 | NR | NR | NR | NR | NR |
| Nikolic/ 2014/ Serbia [70] | 78.6 | 58.7 | ≈53 | ≈50 | ≈42 | NR | NR | 51 | >22 | NR | 23 (>16) 1-,2-,6-yr 68.3%, 46.7% and 38.1% |
22 (1-83) |
| Passot/ 2012/ France [21] | 77 | 51 | NR | NR | 33 | NR | NR | 36.2 | NR | NR | NR | 58.5 (1-183) |
| Passot/ 2016/ France [104] | ≈83 | ≈65 | ≈51 | ≈38 | 31 | NR | 30 | 36 | NR | NR | 11 | NR |
| Pilati/ 2003/ Italy [71] | ≈68 | 31 | NR | NR | NR | 0 | 35 | 18 | NR | 13 | NR | 14.5 |
| Prada-Villaverde/ 2014/ Spaini [72] | ≈85 | ≈63 | ≈45 | ≈38 | ≈35 | NR | NR | 31.4 | NR | NR | NR | NR |
| Quenet/ 2011/ France [73] | ≈92 | ≈72 | ≈36 | ≈47 | ≈44 | 4.1 | 47.2 | 41 | 32–60 | NR | 15.7 (12–18) (RFS) | 48.5 (41.0–56.3) |
| Rivard/ 2014/ Canada [74] | ≈88 (Colon) ≈80 (Rectal) |
≈68 (Colon) ≈24 (Rectal) |
≈46 (Colon) ≈30 (Rectal) |
NA | NA | NR | NR | ≈31 (Colon) ≈18 (Rectal) |
NR | NR | 10.9 3-yr, 15% |
30.3 (2-88) |
Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy